Long Covid–the disease encompassing the post-acute sequelae of SARS-CoV-2 (PASC)—
affects millions of people around the world. Prevention of PASC is an urgent public health …

Importance Post–COVID-19 condition (PCC), also known as long COVID, affects many
individuals. Prevention of PCC is an urgent public health priority. Objective To examine …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …

We conducted a retrospective cohort study to assess whether treatment with
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …

Importance Postmarket analysis of individuals who receive nirmatrelvir and ritonavir
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …